We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.13% | 7.61 | 7.55 | 7.66 | 7.62 | 7.57 | 7.62 | 1,626,365 | 21:01:29 |
From May 2019 to May 2024
By Sonia Amaral Rohter
Bayer AG (BAYN.XE) said on Friday that Amikacin Inhale, an integrated drug-device combination being tested in patients with a type of pneumonia, failed to meet the primary objective in a phase 3 trial.
The trial was studying Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia. In the study, Amikacin Inhale failed to demonstrate superiority over the placebo and therefore did not meet either the primary or secondary objectives of the trial. Amikacin Inhale is a drug-device combination product that combines a specially formulated version of the antibiotic amikacin with an inhalation system developed by Nektar Therapeutics (NKTR) to deliver the drug to the patient's lungs.
The Amikacin Inhale program is being developed through a collaboration with Nektar Therapeutics.
Write to Sonia Amaral Rohter at sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
November 24, 2017 03:31 ET (08:31 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
